Drugs that contain Duvelisib
1. Copiktra patents expiration
Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(5 years from now) | |
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(4 years from now) | |
| US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(7 years from now) | |
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll); For the treatment of patients with follicular lymphoma (fl)
Dosage: CAPSULE;ORAL
More Information on Dosage
COPIKTRA family patents
